|
業務類別
|
-- |
|
業務概覽
|
Camurus AB is a science-led biopharmaceutical company focused on developing and commercializing long-acting medicines for the treatment of severe and chronic diseases. It has two approved products, including treatments for opioid dependence, and a development pipeline supported by its FluidCrystal technology. Its clinical pipeline includes product candidates for conditions such as pain, cancer, endocrine, and metabolic diseases, developed in-house and in collaboration with international pharmaceutical companies. Its pipeline programs include CAM2029 for acromegaly, gastroenteropancreatic neuroendocrine tumors, and polycystic liver disease; CAM2038 for chronic pain; CAM4072 for genetic obesity disorders; CAM2043 for Raynaud's phenomenon; CAM4071 for endocrine disorders, among others. |
| 公司地址
| Rydbergs torg 4, Lund, SWE, SE-224 84 |
| 電話號碼
| +46 462865730 |
| 傳真號碼
| +46 462865739 |
| 公司網頁
| https://www.camurus.com |
| 員工數量
| 285 |
| Mr. Fredrik Tiberg |
Director, President, Chief Scientific Officer and Chief Executive Officer |
-- |
29/04/2026 |
| Mr. Anders Vadsholt |
Chief Financial Officer |
-- |
29/04/2026 |
|
|
| Mr. Per Olof Wallstrom |
Chairman of the Board |
29/04/2026 |
| Mr. Fredrik Tiberg |
Director, President, Chief Scientific Officer and Chief Executive Officer |
29/04/2026 |
| Ms. Hege Hellstrom |
Independent Director |
29/04/2026 |
| Mr. Jakob Lindberg |
Independent Director |
29/04/2026 |
| Mr. Stefan K Persson |
Director |
29/04/2026 |
| Dr. Elisabeth Bjork, M.D.,PhD |
Independent Director |
29/04/2026 |
| Dr. Robert McQuade, PhD |
Independent Director |
29/04/2026 |
| Ms. Erika Soderberg Johnsson |
Independent Director |
29/04/2026 |
|
|
|
|
